English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Peptide YY (PYY 3-36 ) infused to levels within the physiological range reduces appetite and food intake in humans without nausea. However, PYY 3-36  has previously been shown to cause nausea at higher doses.Methods   We studied the relationship of PYY 3-36 , nausea and food intake in six volunteers, using three different PYY 3-36  preparations infused to achieve supraphysiological PYY plasma levels.Results   Supraphysiological levels of PYY caused nausea in five subjects ( P &lt; 0.05). Although PYY 3-36  increased satiety ( P &lt; 0.05) and reduced food intake ( P &lt; 0.05), no greater enhancement of satiety or inhibition of food intake was observed compared with previous reports.Conclusions   This study cautions against the use of supraphysiological doses of PYY 3-36  as it may increase nausea with no benefit in food reduction.

Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake

Supraphysiological doses of intravenous PYY_3-36 cause nausea, but no additional reduction in food intake